What is the role of persister cells in Pseudomonas aeruginosa infections and how can therapies be developed to eradicate them?

May 14, 2014 ... A Pseudomonas aeruginosa type VI secretion phospholipase D effector targets both prokaryotic and eukaryotic cells. Cell Host Microbe. 2014 May ... Mar 14, 2024 ... INTRODUCTION. Pseudomonas aeruginosa is one of the most important and most commonly considered pathogens in the differential diagnosis of ... The bacteria are found widely in the environment, such as in soil, water, and plants. They usually do not cause infections in healthy people. If an infection ... Mar 31, 2015 ... We establish the P. aeruginosa essential genome with statistical precision in laboratory media and CF sputum. Apr 11, 2024 ... Key points · Pseudomonas aeruginosa (P. aeruginosa) infections typically occur in healthcare settings. · Good hand hygiene and infection ... The emergence of colistin-resistant Pseudomonas aeruginosa in cystic fibrosis (CF) patients, particularly after long-term inhalation treatments, has been ... Some P. aeruginosa are becoming more resistant to even antibiotics of last resort, and are described as multidrug-resistant. Pseudomonas Aeruginosa Infection. A Pseudomonas aeruginosa infection is a condition that can affect your skin, blood, lungs, GI tract and other parts of your ... aeruginosa eradication rate of 40% (95% CI 34–45%; p<0.00001), with no significant heterogeneity (I2=0%). Combined systemic and inhaled antibiotic treatment was ... Multidrug efflux pumps are among the main Pseudomonas aeruginosa antibiotic-resistance determinants. Besides, efflux pumps are also involved in other ...